

# Rituximab in Severe Lupus Nephritis: Early B-Cell Depletion Affects Long-Term Renal Outcome

Catherine Melander,\* Marion Sallée,\* Pierre Trolliet,<sup>†</sup> Sophie Candon,<sup>‡</sup> Xavier Belenfant,<sup>§</sup> Eric Daugas,<sup>||</sup> Philippe Rémy,<sup>¶</sup> Virginie Zarrouk,\*\* Evangéline Pillebout,<sup>††</sup> Christian Jacquot,<sup>‡‡</sup> Jean-Jacques Boffa,<sup>§§</sup> Alexandre Karras,<sup>‡‡</sup> Virginie Masse,<sup>|||</sup> Philippe Lesavre,\* Caroline Elie,<sup>|||</sup> Isabelle Brocheriou,<sup>¶¶</sup> Bertrand Knebelmann,\* Laure-Hélène Noël,<sup>\*\*\*</sup> and Fadi Fakhouri\*

\*Department of Nephrology, Assistance Publique—Hôpitaux Paris (AP-HP), Université Paris Descartes, Hôpital Necker, Paris, France; <sup>†</sup>Department of Nephrology, Centre Hospitalier Lyon-Sud, Lyon, France; <sup>‡</sup>Department of Immunology, AP-HP, Hôpital Necker, Paris, France; <sup>§</sup>Department of Nephrology, Centre Hospitalier Intercommunal André Grégoire, Montreuil, France; <sup>||</sup>Department of Nephrology, AP-HP, Hôpital Bichat, Paris, France; <sup>¶</sup>Department of Nephrology, AP-HP, Hôpital Henri Mondor, Créteil, France; \*\*Department of Internal Medicine, AP-HP, Hôpital Beaujon, Clichy, France; <sup>††</sup>Department of Nephrology, AP-HP, Hôpital Saint-Louis, Paris, France; <sup>‡‡</sup>Department of Nephrology, AP-HP, Hôpital Européen Georges Pompidou, Paris, France; <sup>§§</sup>Department of Nephrology, AP-HP, Hôpital Tenon, Paris, France; <sup>|||</sup>Department of Biostatistics, AP-HP, Université Paris Descartes, Hôpital Necker, Paris, France; <sup>¶¶</sup>Department of Pathology, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France; <sup>\*\*\*</sup>Department of Pathology, AP-HP, Hôpital Necker, Paris, France

**Background and objectives:** Standard treatment for lupus nephritis, including corticosteroids and cyclophosphamide, is efficient but is still associated with refractory or relapsing disease, or severe deleterious effects. Rituximab, a monoclonal chimeric anti-B cell antibody, is increasingly used in patients with lupus nephritis, but reported series were small and had a short follow-up.

**Design, setting, participants, & measurements:** The authors analyzed clinical and histologic data of 20 patients who were treated with rituximab for lupus nephritis and followed up for at least 12 mo.

**Results:** Nineteen women and one man received rituximab as induction treatment for an active class IV (15 cases) or class V (5 cases) lupus nephritis. Rituximab was given for lupus nephritis refractory to standard treatment (12 cases), for relapsing disease (6 cases), or as first-line treatment (2 cases). Three patients received cyclophosphamide concomitantly with rituximab. Ten received new injections of rituximab as maintenance therapy. Side effects included mainly five infections and four moderate neutropenias. After a median follow-up of 22 mo, complete or partial renal remission was obtained in 12 patients (60%). Lupus nephritis relapsed in one patient, who responded to a new course of rituximab. The achievement of B cell depletion 1 mo after rituximab, which negatively correlated with black ethnicity and hypoalbuminemia, was strongly associated with renal response. Rapidly progressive glomerulonephritis did not respond to rituximab.

**Conclusion:** Rituximab is an interesting therapeutic option in relapsing or refractory lupus nephritis when early B cell depletion is obtained.

*Clin J Am Soc Nephrol* 4: 579–587, 2009. doi: 10.2215/CJN.04030808

**S**ystemic lupus erythematosus (SLE) is an autoimmune disease with polymorphic expression. One of its most severe manifestations is lupus nephritis (LN) which is associated with an increased morbidity and mortality.

The standard treatment for active proliferative LN (class III and IV) includes corticosteroids (CS) and cyclophosphamide

(CYP). This regimen has been shown to be more efficient than CS alone (1), and the prognosis of LN has greatly improved in the last decades (2). Nevertheless, the occurrence of resistant or relapsing LN (respectively 20% and 33% after first-line treatment; 2), as well as the high frequency of deleterious effects of CYP and CS, make the use of alternative treatments necessary.

In membranous LN, there is no generally admitted standard treatment, and the development of effective therapeutic regimens with little toxicity is needed in patients with persistent severe nephrotic syndrome (3). Mycophenolate mofetil (MMF) seems to be a promising treatment in both proliferative and membranous LN, but long-term data on efficacy are still lacking (4).

Received August 14, 2008. Accepted December 30, 2008.

Published online ahead of print. Publication date available at [www.cjasn.org](http://www.cjasn.org).

**Correspondence:** Dr. Fadi Fakhouri, Molecular Genetics and Rheumatology Section, Faculty of Medicine, Imperial College, Hammersmith Campus, London, United Kingdom. Phone: 00442083832379; Fax: 00442083832379; E-mail: [f.fakhouri@imperial.ac.uk](mailto:f.fakhouri@imperial.ac.uk)

Although the pathogenesis of SLE remains not fully understood, hyperreactive B cells seem to play a central role through the production of auto-antibodies, antigen processing and presentation, recruitment of auto-reactive T cells, interaction with antigen presenting cells, and secretion of cytokines (reviewed in (5)). Targeting B cells could therefore be an interesting therapeutic option in SLE, especially LN.

Rituximab (RTX), a monoclonal chimeric antibody directed against CD20, induces a profound and long-lasting B cell depletion. It was initially successfully developed for the treatment of non-Hodgkin lymphoma (6), and subsequently used in various auto-immune diseases, including SLE (7). Few open studies have evaluated the use of RTX in SLE patients. Overall, results were encouraging. However, these series included a small number of patients with active and/or severe LN and long-term data regarding the outcome of patients with LN treated with RTX are extremely scarce.

Our multicenter study aimed to assess long-term ( $\geq 12$  mo) efficacy and safety of RTX in 20 SLE patients with severe proliferative or membranous LN.

## Patients and Methods

We identified retrospectively twenty patients in eight French nephrology centers treated with RTX for LN between October 2003 and December 2006. Inclusion criteria were: 1) diagnosis of SLE according to the American College of Rheumatology (ACR) (8); 2) available follow-up  $\geq 12$  mo; 3) active class III or IV, or class V LN established by kidney biopsy performed less than 3 mo before RTX initiation (in the absence of contra-indication).

Medical files were reviewed and relevant clinical and biologic data were recorded. GFR (eGFR) was estimated according to the simplified Modification of Diet in Renal Disease Study equation (9). Circulating B cells level in the peripheral blood were evaluated by the detection of CD19+ cells by flow cytometry. B cell depletion was defined as a CD19+ cell count  $\leq 5/\text{mm}^3$  and  $\leq 1\%$  total lymphocytes count. Assay for RTX-specific human antichimeric antibodies (HACAs) was performed as described previously (10). Positivity threshold for HACAs is 20%.

All kidney biopsy specimens were blindly reviewed by two expert pathologists (LH Noël and I. Brocheriou), and graded according to the International Society of Nephrology/Renal Pathology Society 2003 classification (11).

**Renal response and remission.** Renal insufficiency is defined as an eGFR  $< 60$  ml/min/1.73 m<sup>2</sup>. Partial renal remission (PR) was defined as a decrease in 24 h proteinuria  $> 50\%$ , and stabilization of eGFR. Complete renal remission (CR) was defined as 24 h proteinuria level  $< 0.5\text{g/d}$ , absence of hematuria and a normal eGFR ( $\geq 60$  ml/min/1.73 m<sup>2</sup>) or an improvement of eGFR  $> 50\%$  from baseline value.

**Statistical analysis.** Results are expressed as frequencies and percentages for categorical variables and as medians (range) for continuous variables. Differences between groups for categorical variables were tested using the Fisher's exact test, and differences between groups for continuous variables were tested using the Wilcoxon rank sum test. Comparison of corticosteroid dosage before and after treatment was analyzed by paired Wilcoxon signed rank test with continuity correction. P values smaller than 0.05 were considered as statistically significant. Statistical analyses were performed with the R software (<http://www.R-project.org>).

## Results

### Baseline Characteristics

Twenty patients (19 women and one man) were included in the study. Clinical and biologic characteristics are shown in Tables 1 and 2. Three patients (pts 2, 6, and 9) have already been reported elsewhere (12). Twelve patients had already experienced at least one LN relapse, including seven patients with at least two LN relapses. Eighteen patients (90%) had already received at least one line of IS therapy, including intravenous CYP in 15 patients, with a median cumulative dose of 6 g (3–12). Upon RTX initiation, renal involvement was severe as nephrotic syndrome was present in 18 patients and acute renal insufficiency in 9, among whom three had an eGFR  $< 15$  ml/min/1.73 m<sup>2</sup> (Table 2). Three patients did not undergo kidney biopsy in the 3 mo before RTX because of temporary contra-indication: severe thrombocytopenia in patients 13 and 16; anti-vitamin K treatment in patient 15. For these patients, the most recent kidney biopsy (5 yr, 1.5 yr and 2.5 yr before RTX for patients 13, 15 and 16 respectively) showed a class V LN. In this type of LN, kidney biopsy is not mandatory before the start of IS in case of persisting severe nephrotic syndrome.

Kidney biopsy disclosed class IV LN in 15 patients (including four with class IV+V), and class V in five patients (Table 2).

### Treatment

RTX was administrated weekly for 4 wk at a dosage of 375 mg/m<sup>2</sup> of body surface area, except for patients 8 and 9 who received three injections. Treatment associated with RTX varied (Table 2). Three patients had received CYP less than 3 mo before study entry, and three others received CYP concomitantly with RTX. Ten patients received RTX as a maintenance therapy (number of RTX injections: one to 11; median: 2). Retreatment with RTX was decided because of increase of B cell count  $> 5/\text{mm}^3$  mainly in patients in whom all previous treatments including CYP and/or MMF had failed to induce long-term remission. RTX maintenance therapy was associated in four cases out of 10 with another immunosuppressive therapy (MMF in patients 13, 18 and 19 and AZA in patient 15).

### Global Renal Outcome

After a median follow-up of 22 mo (range 10 to 51), complete (CR) and partial (PR) renal remission were obtained in seven and 5 patients respectively, corresponding to an overall renal response of 60%. CR or PR occurred early (less than 6 mo) in six patients (pts 3, 6, 12, 15, 19 and 20), at 12 mo in 5 patients (pts 5, 7, 9, 17 and 18) and at 26 mo in patient 2.

### Renal Outcome in Proliferative LN

Among the 15 class IV LN patients, 66% responded to RTX, including 5 CR and 5 PR. Only one of the responders relapsed during follow-up: patient 18 reached PR at M3 and relapsed at M9. She subsequently received two injections of RTX and achieved PR. Among the 5 treatment failures, four underwent chronic hemodialysis.

Table 1. Baseline characteristics of 20 patients treated with rituximab (RTX) for a lupus nephritis (LN)

Pt/Gender (Age) Ethnicity	SLE/LN duration (years)	SLE Extrarenal Manifestations	Complement/ AntiDNA at inclusion	Previous IS Therapy	RTX Indication
1/F (24) W	2/1	<b>S, H, Se, GS</b>	↓ / +	<b>Cs CYP (5) MMF HCQ</b>	Rf
2/F (20) W	7/3	<b>S, A, Se, H</b>	↓ / +	<b>Cs CYP (4) AZA HCQ</b>	Rf
3/F (27) W	2/2	<b>S, A, APL, H</b>	N / +	<b>Cs CYP (3) MMF HCQ MTX</b>	Rf
4/M (23) B	6/2	<b>S, A, APL, N, Se</b>	↓ / +	<b>Cs CYP (7) MMF AZA HCQ</b>	Rf
5/F (33) As	1/1	<b>F, A, H, M</b>	↓ / +	<b>Cs CYP (6) MMF</b>	Rf
6/F (20) W	9/5	<b>S, A, H</b>	↓ / +	<b>Cs CYP (3) MMF AZA MTX</b>	Rf
7/F (18) B	2/1	<b>F, S, A, H</b>	↓ / +	<b>Cs CYP (6) MMF</b>	Rf
8/F (27) B	1/0	<b>S, A, Se, H</b>	↓ / +	<b>Cs CYP (3)</b>	Rf
9/F (19) W	8/6	<b>Ad, Hep, Ret, H</b>	N / +	<b>Cs CYP (12) MMF HCQ</b>	Rf
10/F (31) W	4/4	<b>A, Se, PE, H</b>	↓ / +	<b>Cs CYP AZA</b>	Rf
11/F (23) B	8/5	<b>S, A, H</b>	↓ / na	<b>Cs CYP (6) AZA HCQ</b>	Rf
12 /F (28) As	0/0	<b>S, Se, TMA, Sp</b>	↓ / +	—	1st
13/F (24) B	12/12	<b>A, Se, H</b>	↓ / +	<b>Cs CYP (8) AZA HCQ</b>	Rf
14/F (37) B	1/1	<b>F, S, N, PE, H</b>	N / +	<b>Cs HCQ</b>	Rf
15/F (35) W	4/4	<b>F, S, A, CT, H</b>	↓ / +	<b>Cs; CYP (9) MMF AZA</b>	Rf
16 /F (17) B	2/2	<b>F, S, H, A, Se</b>	↓ / -	<b>Cs MMF HCQ</b>	Rf
17/F ( 21) W	1/1	<b>APL</b>	N / +	—	1st
18/F (22) As	5/4	<b>A, H, Ad, Sp</b>	↓ / +	<b>Cs CYP (7) MMF</b>	Rf
19/F (32) W	3/1	<b>S, A, H</b>	↓ / -	<b>Cs CYP (4) MMF HCQ MTX</b>	Rf
20/F (31) As	8/8	<b>S, A, N, En</b>	↓ / +	<b>Cs MMF AZA</b>	Rf

Extra-renal manifestations in bold: active manifestation at the time of RTX initiation. Therapy in bold: taken in the 3 mos before RTX. Age is in years. Pt, patient; F, female; As, Asian; B, black ethnicity; W, white ethnicity. SLE, systemic lupus erythematosus. S, cutaneous manifestation; H, haematological manifestation; Se, serositis; GS, Gougerot Sjögren disease; A, arthritis; APL, antiphospholipid syndrome; N, neurological manifestations; F, fever; M, myositis; Ad, adenomegalia; Hep, hepatitis; Ret, retinitis; PE, pulmonary embolism; TMA, thrombotic microangiopathy; Sp, splenomegalia; CT, cerebral thrombophlebitis; En, endocarditis; Complement = C3 and C4 levels: ↓, low; N, normal; Anti-DNA: anti-dsDNA antibody level: +, positive (above laboratory positivity level); -, negative; IS, immunosuppressive; Cs, corticosteroids, CYP, cyclophosphamide; CYP (X), cumulated dose of CYP in grams; MMF, mycophenolate mofetil; HCQ, hydroxychloroquine; AZA, azathioprine; MTX, methotrexate; Rf, refractory disease; Rl relapsing disease; 1<sup>st</sup>, first line treatment for LN.

### Renal Outcome in Rapidly Progressive Glomerulonephritis (RPGN)

None of the three patients who initially presented with RPGN responded to treatment. Patients 10 and 11 presented with acute renal failure as a result of RPGN and were started on hemodialysis at the same time as they received CS, CYP and RTX. Hemodialysis could not be discontinued. Patient 8 had less severe RPGN. Lack of response 45 d after the last infusion of CYP urged the physician to prescribe RTX. She failed to respond and was started on hemodialysis 6 mo after RTX initiation.

### Renal Outcome in Membranous LN

Two of the five patients treated with RTX for class V LN reached CR, with no relapse at last follow-up. Patient 13 did not respond to RTX. She had not had a recent kidney biopsy before treatment. One can not exclude that chronic lesions (*i.e.* secondary focal segmental glomerulosclerosis) may have hampered renal response. Patient 16 did not respond to RTX, evolved to class III+V LN on control kidney biopsy and died at M10.

### Predictive Factors of Renal Response

Absence of renal remission was significantly associated with black ethnicity (black patients: 75% among nonresponders *versus* 8% among responders,  $P = 0.004$ ) (Table 3) and with the absence of B cell depletion one month after RTX initiation (B cell depletion at M1: 11/11 among responders *versus* 1/6 among nonresponders;  $P < 0.001$ ). Of note, in two patients (pts 1 and 14), B cell depletion was not achieved until M3. Neither of them responded to treatment, suggesting the importance of early B cell depletion.

**Repeated Kidney Biopsy.** Repeated kidney biopsy was performed in nine patients, who were either in partial remission or not responding, to guide further treatment. In all, median histologic activity decreased from 9/24 (0 to 11) to 2.5/24 (0 to 8). In 5 responders (3 CR, two PR) with baseline class IV LN, repeated kidney biopsy confirmed clinical response by showing a decrease in activity index (Table 2 and Figure 1). Immunohistochemistry for CD20+ cells was available in patient 4 (Figure 1). This patient presented with severe class IV LN refractory to treatment associating CYP and CS, followed by MMF. Renal biopsy performed before RTX initiation

Table 2. Renal features and treatment at baseline and at the end of follow-up

Pt	At RTX Initiation (Baseline)				CD19 + Depleted M1	F-Up M	After RTX (End of Follow-Up)				Response M12/End
	Pu (g/d)/Alb (g/L)/eGFR (ml/min/1.73 m <sup>2</sup> )	KB	IS	IS			Pu (g/d)/Alb (g/L)/eGFR (ml/min/1.73 m <sup>2</sup> )	KB	Date/Result	IS	
1	3/27/120	IVG(10/0)	Cs (0.5)	-	23	3/17/107	M14:IVG + V (3/1)	Cs (0.2) MMF	NR/NR		
2 <sup>a</sup>	5/28/74	IVG + V(10/1)	Cs (1) <sup>b</sup> HCQ	+	48	0.3/37/135	M26:IVS + V (1/4)	Cs (0.1) HCQ	NR/CR		
3	5/19/71	IVS + V(6/7)	Cs (0.1) <sup>b</sup> HCQ	na	20	0.2/31/119	Cs (0.1) MMF HCQ	Cs (0.1) MMF HCQ	PR/CR		
4	04/11/58	IVG + V(8/8)	Cs (0.3) <sup>b</sup> MMF	-	13	na/28/HD	M2:IVG (8/10)	Cs (0.1) CYP (4)	HD/HD		
5 <sup>a</sup>	5/24/105	IVS <sup>c</sup>	Cs (1) <sup>b</sup>	+	21	1/36/83		Cs (0.1)	PR/PR		
6 <sup>a</sup>	6/26/52	IVG + V(11/6)	Cs (1) <sup>b</sup>	+	37	0.5/40/82	M37:III (0/3)	Cs (0.2)	PR/CR		
7	0.5/40/150	IVS(6/2)	Cs (0.3) MMF	+	42	0/40/154	M16:III + V (2/1)	Cs (0.1) AZA HCQ	PR/CR		
8	9/14/16	IVG(10/8)	Cs (0.6) <sup>b</sup>	-	21	na/14/HD		Cs (0.2)	HD/HD		
9 <sup>a</sup>	7/20/46	IVS(11/4)	Cs (1) <sup>b</sup> HCQ	+	51	0.5/34/52	M5:IVS (2/8)	Cs (0.1)	PR/PR		
10	3/28/HD	IVG <sup>c</sup>	Cs (1) <sup>b</sup> CYP (4)	na	31	na/35/HD		Cs (0.1)	HD/HD		
11	3/20/HD	IVG(13/6)	Cs (1) <sup>b</sup> CYP (4)	na	31	na/35/HD		Cs (0.2) AZA HCQ	HD/HD		
12	1.5/29/47	IVG(7/3)	Cs (1) <sup>b</sup> CYP (3)	+	17	0/46/77		Cs (0.2) MMF HCQ	CR/CR		
13 <sup>a</sup>	5/23/66	V <sup>d</sup>	Cs (0.7) <sup>b</sup> HCQ	+	19	4/25/65		Cs (0.4) HCQ MMF	NR/NR		
14	9/19/102	V	Cs (0.2) MMF HCQ	-	12	05/11/88		Cs (0.1) CSA HCQ	NR/NR		
15 <sup>a</sup>	4/26/127	V <sup>d</sup>	Cs (0.5) <sup>b</sup>	+	33	0/35/122		AZA	CR/CR		
16 <sup>a</sup>	8/18/133	V <sup>d</sup>	Cs (1.5)	-	10 <sup>e</sup>	4/24/53	M3:III + V (8/0)	Cs (0.5) CYP (2)	NR		
17 <sup>a</sup>	7/22/147	V	-	+	13	0.3/33/116		—	PR/CR		
18 <sup>a</sup>	11/20/90	IVG + V(7/4)	Cs (0.25)	+	27	1/35/102	M13:IVG + V (5/6)	Cs (0.06) HCQ	PR/PR		
19	7/23/9	IV <sup>c</sup>	Cs (1) <sup>b</sup> HCQ	+	14	1.6/37/16	M7:IVG (9/8)	Cs (0.4) HCQ MMF	PR/PR		
20 <sup>a</sup>	25/22/26	IVG + V(8/6)	Cs (1.2)	+	24	1/35/52		Cs (0.2) MMF	PR/PR		

Pt, patient; RTX, rituximab; IS; immunosuppressive therapy; Pu, proteinuria; Alb, albuminemia; eGFR, estimated glomerular filtration rate; KB, kidney biopsy; M1, one month after RTX initiation; F-up, follow-up; M, months; Cs, corticosteroids; Cs(X), dose of oral Cs in mg/kg/day; HCQ, hydroxychloroquine; MMF, mycophenolate mofetil; CYP, cyclophosphamide; AZA, azathioprine; CSA, cyclosporine A; KB interpretation: S, segmental; G, global; (activity index /24; chronicity index /12); na, not available; NR, absence of renal remission; PR, partial renal remission; CR, complete renal remission; PR, partial renal remission; HD, haemodialysis.  
<sup>a</sup>RTX maintenance therapy. <sup>b</sup>High-dose intravenous corticosteroid injection. <sup>c</sup>Kidney biopsy specimen not available for blinded reading. <sup>d</sup>Kidney biopsy performed more than 3 months before RTX initiation. <sup>e</sup>Deceased.



Table 3. Factors associated with partial or complete renal remission at the end of follow-up

Factor	Renal remission at end of follow-up		P
	+	-	
	(n = 12)	(n = 8)	
Median age, years (range)	24.5 (18 to 35)	24 (17 to 37)	NS
Black ethnicity, n (%)	1 (8)	6 (75)	0.004
Class III/IV LN, n (%)	10 (83)	5 (62)	NS
RPGN, n (%)	0	3 (37)	0,05
Median Pu, g/day (range)	5.5 (0.5 to 25)	4.5 (3 to 9)	NS
Median serum Alb, g/L (range)	24.5 (19 to 40)	19.5 (11 to 28)	0.08
Median eGFR, ml/min/1.73 m <sup>2</sup> (range)	72 (9 to 150)	62 (0 to 133)	NS
Median C3, % normal (range)	44 (15 to 121)	39 (30 to 130)	NS
Baseline positive anti-dsDNA Ab, n (%)	11 (92)	6/7 (86)	NS
Negative anti-dsDNA Ab at end of follow-up (among positive at baseline), n (%)	5 (45%)	2 (33%)	NS
IV Cs, n (%)	8 (75%)	4 (50%)	NS
CYP, n (%)	1 (8%)	2 (25%)	NS
MMF, n (%)	1 (8%)	2 (25%)	NS
B cell depletion at M1	11/11	1/6	<0.001
Overall B cell depletion	11/11	3/6	0.03

P values are by Fisher's exact test for categorical data and by Wilcoxon rank sum test with continuity correction for continuous data. NS, not significant; LN, lupus nephritis; RPGN, rapidly progressive glomerulonephritis; Pu, baseline proteinuria; serum Alb, baseline albuminemia; eGFR, baseline estimated glomerular filtration rate; C3: baseline C3 complement; anti-dsDNA Ab, anti-double stranded DNA antibody; IV Cs, intravenous corticosteroids associated with rituximab; CYP, cyclophosphamide associated with rituximab; MMF, mycophenolate mofetil associated with RTX; M1, 1 mo after rituximab initiation.

showed massive interstitial infiltrate with a majority of CD20+ cells. Peripheral B cell depletion was not obtained, and the patient's renal function continued to deteriorate. Very surprisingly, a control renal biopsy performed 2 mo later showed complete resolution of the B cell inflammatory infiltrate, even though glomerular lesions had significantly progressed.

**Extrarenal Manifestations.** Treatment was efficient on hematologic manifestations of SLE. Auto-immune hemolytic anemia in patients 10 and 11, and thrombotic microangiopathy in patient 12 resolved after RTX. Overall, among the twelve patients who had hematologic disorders at inclusion, only six still did at the end of follow-up.

**Corticosteroid-Sparing Effect.** Treatment enabled significant CS sparing as the median dose of oral CS decreased from 0.7 mg/kg per d (0 to 1.5) to 0.1 mg/kg per d (0 to 0.5) ( $P < 0.001$ ). In responders, the decrease in median CS was important, going from 1 mg/kg per d (0 to 1.2) to 0.1 mg/kg per d (0 to 0.4), whereas in patients who did not respond to treatment and did not require hemodialysis it decreased only from 0.6 mg/kg per d (0.2 to 1.5) to 0.3 mg/kg per d (0.1 to 0.5).

**B Cell Depletion.** B cell depletion at M1 was obtained in 12 of 17 patients. Duration of B cell depletion was available for 11 patients and ranged from 3 to 12 mo (median 6 mo). Depletion failure was significantly associated with black ethnicity (80% versus 17%;  $P = 0.03$ ) and with hypoalbuminemia ( $18 \pm 6$  g/L versus  $26 \pm 5$  g/L;  $P = 0.02$ ) (Table 4).

**HACA.** Assay for HACA, available for nine patients (Pts 2, 4, 6, 8, 9, 13, 15 to 17), was positive in two patients (patients 8


and 16), both of whom were of African origin, had deep hypoalbuminemia, failed to reach B cell depletion, and had a pejorative outcome. The population is too small to reach statistical significance, but there could be an association between HACA and B cell depletion failure and/or absence of clinical response. As illustrated in Figure 2, patient 16 had at baseline a peculiar population of CD19+CD20- B cells. She failed to reach CD19+ B cell depletion after RTX therapy. Subsequently, HACAs were detected. Because of renal disease deterioration, she was treated with intravenous CYP at M3. CYP was followed by a disappearance of HACAs and a depletion of CD19+ cells 3 mo after the first CYP injection.

**Anti-Double Stranded DNA Antibodies (anti-dsDNA Ab) and Complement Levels.** Disappearance of anti-dsDNA Ab was obtained in seven of 17 patients. It was not associated either with B cell depletion or with clinical response to treatment. Complement levels normalized in all patients for whom they were initially low, except for patients 4, 8 and 16. There was no association between initial complement levels and either B cell depletion or renal outcome.

#### Adverse Events

RTX injection was overall well tolerated, with two patients experiencing headache (patients 8 and 17), and one nausea (patient 13).

Five patients had infections during follow-up, including two serious events in hemodialysed patients (septic shock and septic arthritis in patients 10 and 11, respectively). The other three



**Figure 1.** Kidney biopsy specimens for patients 9 (panels 1 to 4) and 4 (panels 5 to 8) before and after rituximab (RTX). Patient 9: Kidney biopsy specimen obtained before the start of RTX showed (panel 1) global endocapillary and extracapillary proliferation on light microscopy study (Masson trichrome; original magnification:  $\times 250$ ), and (panel 2) granular Ig G deposits in the mesangium and along the basement membrane on immunofluorescence study (original magnification:  $\times 400$ ). A control kidney biopsy specimen obtained 5 mo after treatment with RTX showed (panel 3) very few active lesions on light microscopy study (Masson trichrome; original magnification:  $\times 250$ ) and (panel 4) a dramatic decrease in IgG glomerular immune deposits on immunofluorescence study (original magnification:  $\times 400$ ). Patient 4: Kidney biopsy specimen obtained before the start of RTX showed (panel 5) global endocapillary proliferation on light microscopy study (Masson trichrome; original magnification:  $\times 400$ ), and (panel 6) nodular CD20+ interstitial inflammatory infiltrate (\*) on peroxidase immunohistochemical study (phenotyping of cells with anti-CD20 monoclonal antibodies; original magnification:  $\times 20$ ). A control kidney biopsy specimen obtained 2 mo after treatment with RTX showed (panel 7) global endocapillary proliferation and glomerular segmental fibrosis, (Masson trichrome; original magnification:  $\times 400$ ) contrasting with the disappearance of nodular CD20+ infiltrate on peroxidase immunohistochemical study (panel 8) (phenotyping of cells with anti-CD20 monoclonal antibodies; original magnification:  $\times 40$ )

patients had viral infections: oropharyngitis while on RTX therapy in patient 6, cutaneous herpes zoster virus in patients 7 and 12 who were taking azathioprine and mycophenolate mofetil respectively at the time.

Four patients had moderate neutropenia (between 800 and 1500/mm<sup>3</sup>) during follow-up, occurring 2 to 18 mo after RTX. In patient 12, it took place after prescription of MMF, and was complicated by a nonsevere bacterial infection. In patients 2, 5 and 11, neutropenia was not complicated, and had no other favoring cause than RTX

Patients 8 and 16 experienced posterior reversible encephalopathy syndrome (PRES) during follow-up. Both failed to respond to RTX and had several risk factors for PRES: active SLE, hypertension, hypervolemia, and/or treatment with high-dose CS. Both evolved favorably with antihypertensive drugs.

Subsequently, patient 16 died at M10 from massive cerebral hemorrhage, in a context of incompletely controlled SLE and hypertension.

## Discussion

RTX is increasingly used in LN. Even though several series have been reported (13–23), limitations preclude reliable conclusions regarding the use of RTX in LN. The largest series (20) included 21 LN, but the only details on renal outcome consisted of a “decrease of median urinary protein creatinine ratio from 446 to 190 mg/mmol at 6 mo, even though this was not statistically significant ( $P = 0.06$ ).” In the series with the longest follow-up (15) (24 mo), there was no information regarding kidney biopsy, and none of the patients had baseline renal insufficiency. To our knowledge, the only study that reported recent kidney biopsy data before treatment and repeated kidney biopsy during follow-up was published by Gunnarson *et al.* (17). Even though very instructive, this study had a short follow-up (6 mo) and included only seven patients, with only one with renal insufficiency. Altogether, only 14 cases of adults treated with RTX for LN and kidney insufficiency have been reported so far. However, patients had a mild kidney insufficiency (eGFR between 40 and 60 ml/mn) and a short follow-up in nine cases (13,17,23).

Compared with these studies, our report included one of the largest numbers of patients and had one of the longest follow-up. Furthermore, our study included many patients with severe disease: nine patients had kidney insufficiency including three RPGN, one-third were of black ethnicity and most had refractory or relapsing disease, despite high-dose conventional treatment.

Therefore, our study provides valuable information regarding RTX efficacy in patients with severe LN. Our study is not controlled, but it is highly unlikely that patients with severe LN and renal insufficiency may be included in randomized controlled trials.

Overall, RTX, associated with CS and/or other IS therapies, showed efficacy in LN in 60% of our patients. This figure is comparable to what was observed in the other studies cited above including LN patients treated with RTX (response rate ranging from 33 to 57% cases). Considering that response to

Table 4. Factors associated with B cell depletion 1 mo after rituximab initiation

Factor	B cell depletion at M1		P
	+	-	
	(n = 12)	(n = 5)	
Median age, years (range)	23 (18 to 35)	24 (17 to 37)	NS
Black ethnicity, n (%)	2 (17%)	4 (80%)	0.027
Median Pu, g/j (range)	5.7 (0.2 to 25)	8 (2.7 to 9.5)	NS
Median serum Alb, g/L (range)	24.5 (20 to 40)	18 (11 to 27)	0.03
Median eGFR, ml/min/1.73 m <sup>2</sup> (range)	70 (9 to 150)	102 (16 to 133)	NS
Median C3, % normal (range)	44 (15 to 96)	39 (30 to 130)	NS
Median C4, % normal (range)	34 (17 to 78)	26 (21 to 101)	NS

B cell depletion is defined as CD19 + cells  $\leq 5/mm^3$  and  $\leq 1\%$ . P values are by Fisher’s exact test for categorical data and by Wilcoxon rank sum test with continuity correction for continuous data. NS, not significant; Pu, baseline proteinuria; Serum Alb, baseline albuminemia; eGFR, baseline estimated glomerular filtration rate; C3: baseline C3 complement; C4: baseline C4 complement.




Figure 2. Patient 16: Evolution of CD19+ and CD20+ cells, and of rituximab-specific human antichimeric antibodies (HACAs) after treatment with rituximab (RTX) and cyclophosphamide (CYP). Full arrows: injection of RTX (375 mg/m<sup>2</sup> of body surface area). Empty arrows: injection of CYP (500 mg).

first-line treatment is 81% at the very best (2), 60% response in severe LN seems quite promising.

Being able to identify the patients who will benefit from such a treatment is an important challenge. In our study, we found a strong association between B cell depletion at M1 and treatment success. Indeed, only one patient in whom B cell depletion was obtained did not have a positive renal outcome, and the achievement of B cell depletion is associated in our study with a high probability of renal remission (92%). Even though these data need to be confirmed, B cell depletion failure at M1 should urge clinicians to use another IS therapy.

Even though B cell depletion is an early predictor of renal response, it would be interesting to predict in which patients it will be obtained before choosing RTX treatment. It is not as yet fully understood why B cell depletion failure is more frequent in SLE (up to 35% (14)) than in other conditions during which RTX is used (close to 0% in rheumatoid arthritis (24)). Our study, and others, open some leads. We found that deep hy-

poalbuminemia, black ethnicity, and possibly HACAs, were associated with depletion failure.

Association between black ethnicity and B cell depletion failure in SLE was shown by Looney *et al.* in 2004 (14). However, in a more recent study by Albert *et al.* (19), such an association was not found. To our knowledge, no link between treatment efficacy and ethnicity was found in other indications of RTX. This possible association between black ethnicity and B cell depletion failure could be explained by peculiar characteristics of B cells in this ethnic group.

Fc $\gamma$ RIIIa polymorphism is a possible explanation for variability in response of SLE to RTX (25). In our study, Fc $\gamma$ RIIIa genotyping was not available. However, the Fc $\gamma$ RIIIa-158F allele, possibly associated to B cell depletion failure, does not seem to be more frequent in African than in Caucasian population (26), suggesting other unrecognized black ethnicity-associated B cell resistance factors.

Given the fact that one of the potential mechanisms of action of RTX is complement-mediated cytotoxicity (27), we hypothesized that complement consumption in LN could account for B cell depletion failure. However, we found no association between C3 or C4 levels and B cell depletion.

Baseline hypoalbuminemia was also found to be associated with B cell depletion failure. To our knowledge, no other study has searched for such an association. In a study of idiopathic membranous nephropathy patients treated with RTX, Fervenza *et al.* (28) showed an association between high rate proteinuria and B cell depletion failure, suggesting a urinary loss of RTX (no data were available regarding albuminemia). This is probably not the case in our study as we found no link between proteinuria level and B cell depletion. We hypothesize that hypoalbuminemia may reflect the activity of LN, and therefore be associated with higher resistance to RTX.

Finally, as previously reported (14,19), we found a tendency to an association between HACAs and B cell depletion failure. However, occurrence of HACAs could be the consequence of inadequate immunosuppression and B cell abnormal features,



and not the cause of B cell depletion failure, as HACAs are not associated with absence of response to RTX in lymphoma (27).

In our study, patients who received CYP concomitantly with RTX did not have a better outcome compared with patients treated with RTX alone. It remains unknown whether adding CYP to RTX may reduce the risk of occurrence of HACAs.

To our knowledge, only 5 patients with RPGN treated with RTX have been reported so far, in an abstract (29). Similarly to our three patients, none of those patients responded to an association of RTX, CYP and CS, even though B cell depletion was obtained in four of them. The fact that RTX seems to have delayed efficacy (12 mo or later in half of our patients) could account for its failure in RPGN.

Data regarding RTX maintenance therapy are still very scarce. In our study, RTX maintenance therapy seems to be a satisfactory therapeutic regimen, enabling long-term remission (more than 4 yr in two patients) with little side effect.

Mechanism of action of RTX in LN is not fully understood. Similarly to previous studies, we found no particular effect of RTX on anti-dsDNA Ab levels. This result suggests that RTX works not solely (or not at all) through auto-antibody depletion but most likely by modulating the complex role of B cells on the immune system, including the B cell/T cell crosstalk.

### Conclusions

RTX could be an interesting option in refractory or relapsing LN, excluding RPGN. B cell depletion at M1 is a useful and early predictor of response. Black ethnicity and profound hypoalbuminemia are probably associated with poor outcome. Prospective studies assessing the efficiency of RTX, with or without CYP, in severe LN are warranted.

### Disclosures

None.

### References

1. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. *Annals Int Med* 135: 248–257, 2001
2. Houssiau FA: Management of lupus nephritis: An update. *J Am Soc Nephrol* 15: 2694–2704, 2004
3. Austin HA, Illei GG: Membranous lupus nephritis. *Lupus* 14: 65–71, 2005
4. Houssiau FA, Ginzler EM: Current treatment of lupus nephritis. *Lupus* 17: 426–430, 2008
5. Christensen SR, Shlomchik MJ: Regulation of lupus-related autoantibody production and clinical disease by toll-like receptors. *Sem Immunol* 19: 11–23, 2007
6. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R: Idec-c2b8 (rituximab) anti-cd20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. *Blood* 90: 2188–2195, 1997
7. Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, Larroche C, Soubrier M, Bouillet L, Dougados M, Fain O, Farge D, Kyndt X, Lortholary O, Masson C, Moura B, Remy P, Thomas T, Wendling D, Anaya JM, Sibilia J, Mariette X: Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. *Ann Rheumatic Dis* 64: 913–920, 2005
8. Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 40: 1725, 1997
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. *Ann Int Med* 130: 461–470, 1999
10. Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, Le Guern V, Aouba A, Sibilia J, Gottenberg J-E, Mariette X: Tolerance and efficacy of rituximab and changes in serum b cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. *Ann Rheumatic Dis* 66: 351–357, 2007
11. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi L-M, Makino H, Moura LA, Nagata M: The classification of glomerulonephritis in systemic lupus erythematosus revisited. *Kidney Int* 65: 521–530, 2004
12. Camous L, Melander C, Vallet M, Squalli T, Knebelmann B, Noël LH, Fakhouri F: Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy. *Am J Kidney Dis* 52: 346–352, 2008
13. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, Portales-Perez D, Baranda L, Abud-Mendoza C, Gonzalez-Amaro R: Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study. *Arthritis Res Ther* 8: R83, 2006
14. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I: B cell depletion as a novel treatment for systemic lupus erythematosus: A phase i/ii dose-escalation trial of rituximab. *Arthritis Rheum* 50: 2580–2589, 2004
15. Smith KG, Jones RB, Burns SM, Jayne DR: Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. *Arthritis Rheum* 54: 2970–2982, 2006
16. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM: Remission of proliferative lupus nephritis following b cell depletion therapy is preceded by down-regulation of the t cell costimulatory molecule cd40 ligand: An open-label trial. *Arthritis Rheum* 52: 501–513, 2005
17. Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF: Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. *Arthritis Rheum* 56: 1263–1272, 2007
18. Tamimoto Y, Horiuchi T, Tsukamoto H, Otsuka J, Mitoma H, Kimoto Y, Nakashima H, Muta K, Abe Y, Kiyohara C, Ueda A, Nagasawa K, Yoshizawa S, Shimoda T, Harada M: A dose-escalation study of rituximab for treatment of sys-



- temic lupus erythematosus and Evans' syndrome: Immunological analysis of b cells, t cells and cytokines. *Rheumatology (Oxford)* 47: 821–827, 2008
19. Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Moore S, Barnack F, Striebich C, Looney RJ, Luning Prak ET, Kimberly R, Zhang Y, Eisenberg R: Variability in the biological response to anti-cd20 b-cell depletion in SLE. *Ann Rheumatic Dis* 67: 1724–1731, 2008
  20. Ng KP, Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G, Isenberg DA: Repeated b cell depletion in treatment of refractory systemic lupus erythematosus. *Ann Rheumatic Dis* 65: 942–945, 2006
  21. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA: B-cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients. *Rheumatology (Oxford)* 44: 1542–1545, 2005
  22. Gillis JZ, Dall'era M, Gross A, Yazdany J, Davis J: Six refractory lupus patients treated with rituximab: A case series. *Arthritis Rheum* 57: 538–542, 2007
  23. Carroll RP, Brown F, Kerr PG: Anti-cd20 antibody treatment in refractory class iv lupus nephritis. *Nephrol Dial Transplant* 22: 291–293, 2007
  24. Silverman GJ: Therapeutic b cell depletion and regeneration in rheumatoid arthritis: Emerging patterns and paradigms. *Arthritis Rheum* 54: 2356–2367, 2006
  25. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ: The relationship of fcγmariia genotype to degree of b cell depletion by rituximab in the treatment of systemic lupus erythematosus. *Arthritis Rheum* 48: 455–459, 2003
  26. Van Den Berg L, Myhr KM, Kluge B, Vedeler CA: Fcγ receptor polymorphisms in populations in Ethiopia and Norway. *Immunology* 104: 87–91, 2001
  27. Smith MR: Rituximab (monoclonal anti-cd20 antibody): Mechanisms of action and resistance. *Oncogene* 22: 7359–7368, 2003
  28. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, Leung N, Cohen IM, Wochos DN, Bergstralh E, Hladunewich M, Cattran DC: Rituximab treatment of idiopathic membranous nephropathy. *Kidney Int* 73: 117–125, 2007
  29. Shirish R, Sangle RJD, Lubna Aslam, Myles J Lewis, Rose Wedgwood, Graham RV Hughes, Ian C. Abbs, David P. D'Cruz.: Rituximab in the treatment of resistant systemic lupus erythematosus: Failure of therapy in rapidly progressive crescentic lupus nephritis: Poster Session: SLE. Boston, Congress of the American College of Rheumatology. 2007

Supplemental information for this article is available online at <http://www.cjasn.org>